41 assets in Plasma Cell Leukemia

Therapeutic assets addressing Plasma Cell Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	BB (66)
Fludarabine Plasma Cell Leukemia	Masonic Cancer Center, University of Minnesota	P2	BB (65)
Dexasone Plasma Cell Leukemia	National Cancer Institute (NCI)	P3	B (63)
Lenalidomide Plasma Cell Leukemia	National Cancer Institute (NCI)	P3	B (63)
Melphalan Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	B (63)
Daratumumab Plasma Cell Leukemia	National Cancer Institute (NCI)	P3	B (60)
Tacrolimus Plasma Cell Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (60)
Carfilzomib Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	B (59)
Teclistamab Plasma Cell Leukemia	National Cancer Institute (NCI)	P3	B (59)
Adriamycin Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	B (58)
Etoposide Plasma Cell Leukemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	B (58)
Bortezomib Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	B (57)
Sirolimus Plasma Cell Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (57)
Allopurinol Plasma Cell Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (54)
Busulfanum Plasma Cell Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (54)
Talquetamab Plasma Cell Leukemia	University of Leeds	P3	CCC (54)
Cis-Diamminedichloroplatinum Ii Plasma Cell Leukemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (53)
CM336 Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Epirubicin Plasma Cell Leukemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (53)
il-15-armored car-t cells Plasma Cell Leukemia	The First Hospital of Jilin University	P2	CCC (53)
Anti-Bcma Car-T Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
Fludeoxyglucose Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	CCC (51)
Isatuximab Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
Plerixafor Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	CCC (51)
Recombinant Human Granulocyte Colony-Stimulating Factor Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	CCC (51)
Recombinant Human Hyaluronidase Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	CCC (51)
ct071 Plasma Cell Leukemia	CARsgen Therapeutics Co., Ltd.	P1/2	CCC (48)
Budesonide Plasma Cell Leukemia	University of Utah	P2	CC (47)
Bcma-Cart Cells Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (43)
Car.70/Il15-Transduced Cb-Nk Cells Plasma Cell Leukemia	M.D. Anderson Cancer Center	P1/2	CC (43)
Car-Gprc5D Plasma Cell Leukemia	Nanjing IASO Biotechnology Co., Ltd.	P1	C (39)
Car-T（Rd140 ） Plasma Cell Leukemia	Peking University People's Hospital	P1	C (39)
Iaso104 Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Early P1	C (39)
Metabolically Armed Bcma Car-T Cells. Plasma Cell Leukemia	Anhui Provincial Hospital	Early P1	C (39)
Itacitinib Plasma Cell Leukemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1	C (38)
Human Bcma Targeted Car-Nk Cells Plasma Cell Leukemia	Hrain Biotechnology Co., Ltd.	Early P1	C (36)
ct0594cp Plasma Cell Leukemia	The First Affiliated Hospital of Soochow University	N/A	D (30)
ari0002h Plasma Cell Leukemia	Fundacion Clinic per a la Recerca Biomédica	P2	NR ()